Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q2 2026 Earnings Presentation
16 slides from Angiodynamics's earnings presentation, Jan 6, 2026
Slide 1: Second Quarter FY 2026 Earnings Results
Second Quarter FY 2026 Earnings Results January 6, 2026
Slide 2: Forward looking statements
Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Q2 FY 2026 Key Takeaways
Q2 FY 2026 Key Takeaways Continued commercial and operational execution positions AngioDynamics to drive accelerated, profitable growth moving forward. Continued Commercial Execution – Q2 FY 2026 YoY Revenue Total Med Tech Med Device Growth* +8.8% +13.0% +5.6% Med Tech YoY Auryon Mech Thrombectomy N
Slide 4: Demonstrated Med Tech Growth Execution
Demonstrated Med Tech Growth Execution Pro Forma Fiscal Year Net Sales ($M) $312 - $314 $293 $271 $257 $235 +14% - 16% Med Tech $206 $106 $127 ~47% of Total Med Tech $186 $79 $96 $56 ~22% of Total $41 $150 $156 $161 $165 $166 $145 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 G* Med Device Med Tech
Slide 5: Q2 FY 2026 Financial Snapshot
Q2 FY 2026 Financial Snapshot Net Sales Segment Revenue Contribution $79.4 Q2 25 Q2 26 $73.0 43% $35.7 +13.0% 55% 45% Pro Forma Growth $31.6 57% Med Device Med Tech Med Device Med Tech +5.6% Segment Gross Margin $41.5 $43.8 Pro Forma Growth 49.1% 65.3% Q2 25 Q2 26 Med Device Med Tech Med Device Med
Slide 6: Med Tech - Auryon
Med Tech - Auryon Combination of Auryon’s best-in-class technology and our commercial strategy have positioned Auryon as a consistently high-growth platform being supported by continued investment in use cases Period Sales YoY Growth Q2 FY 2026 $16.3M 18.6% • Continued penetration into hospital sett
Slide 7: Med Tech – Thrombus Management
Med Tech – Thrombus Management Combination of AngioVac and AlphaVac represent a strong, highly competitive mechanical thrombectomy portfolio which continues to take market share driven by expanded joint commercial strategy Q2 FY 2026 Sales YoY Growth AngioVac $7.5M (7.5%) AlphaVac $3.5M 40.2% Total
Slide 8: Med Tech - NanoKnife
Med Tech - NanoKnife Adoption has continued to accelerate within Prostate as this novel therapy gains traction following receipt of FDA clearance in Dec 2024 Q2 FY 2026 Sales YoY Growth Disposables $5.7M 14.4% Capital $1.6M 61.1% Total $7.3M 22.2% • Continued demand for NanoKnife for prostate drivin
Slide 9: Compelling FY 2026 Financial Outlook
Compelling FY 2026 Financial Outlook supported by balance sheet strength FY 2026 Net Sales ($M) FY 2026 Financial Guidance* $312 - $314 Prior Current Metric Action $293 Guidance Guidance Net Sales Increased $308 - $313M $312 - $314M +14 - 16% Med Tech Med Tech Net Sales Growth Unchanged +14 – 16% +1
Slide 10: Leadership Update
Leadership Update Jim Clemmer to retire upon appointment of successor in fiscal 2027 • On January 6, 2026, the Company announced that AngioDynamics’ President and CEO, Jim Clemmer, intends to retire from the Company during fiscal 2027 upon the appointment of a successor. • The Company’s Board has es
Slide 11: Appendix
Appendix 11
Slide 12: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousand, except per share data) 12
Slide 13: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP Net Loss to Non- Reconciliation of Net Loss to Adjusted GAAP Adjusted Net Loss and EPS and Pro EBITDA and Pro Forma Adjusted EBITDA Forma Adjusted Net Loss and EPS (in thousands, except per share data) (in thousands, except per share data) 13
Slide 14: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP Net Loss to Non- Reconciliation of Net Loss to Adjusted GAAP Adjusted Net Loss and EPS and Pro EBITDA and Pro Forma Adjusted EBITDA Forma Adjusted Net Loss and EPS (in thousands, except per share data) (in thousands, except per share data) 14
Slide 15: Detail of Acquisition, Restructuring and Other Items, net
Detail of “Acquisition, Restructuring and Other Items, net” 15
Slide 16: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) 16